https://doi.org/10.4081/reumatismo.2013.22

Duration of treatment for osteoporosis

Vol. 65 No. 1 (2013)
Submitted: 5 February 2013
Accepted: 15 March 2013
Published: 28 March 2013
Osteoporosis, duration, treatment, alendronate, denosumab.
Abstract Views: 3388
PDF: 1210
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Luca Idolazzi
Unità di Reumatologia, Dipartimento di Medicina, Università di Verona, Italy.
A. Fassio
Rheumatology Unit, University of Verona, Italy.
D. Gatti
Rheumatology Unit, University of Verona, Italy.
S. Tamanini
Rheumatology Unit, University of Verona, Italy.
O. Viapiana
M. Rossini
S. Adami
silvano.adami@univr.it
Many treatments for postmenopausal osteoporosis with proven efficacy in lowering fracture risk had become available since many years now. In the last few years the issue about treatment duration has become a matter of importance. In this paper the pivotal trials for alendronate, risedronate, zoledronate and other anti reabsorptive drugs such as denosumab are revised with particular attention to the extension studies aimed to verify the effect of drug discontinuation. The results of the review highlight differences among the available drugs and the practical clinical consequences also in terms of cost-effectiveness.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Idolazzi, L., Fassio, A., Gatti, D., Tamanini, S., Viapiana, O., Rossini, M., & Adami, S. (2013). Duration of treatment for osteoporosis. Reumatismo, 65(1), 22–35. https://doi.org/10.4081/reumatismo.2013.22

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Similar Articles

<< < 2 3 4 5 6 7 8 9 10 11 > >> 

You may also start an advanced similarity search for this article.